Q3 Earnings Estimate for ALGS Issued By HC Wainwright

Key Points

• HC Wainwright forecasts Aligos Therapeutics' Q3 2025 earnings at ($2.26) per share, maintaining a "Buy" rating and a $50.00 price target.
• The company's recent earnings report showed a loss of ($1.53) per share, surpassing expectations of ($2.35) by $0.82, with revenue of $0.97 million.
• Institutional investors hold 60.43% of Aligos Therapeutics stock, with significant increases in positions by Geode Capital Management and Adage Capital Partners.

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Aligos Therapeutics in a research note issued on Monday, August 18th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($2.26) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Aligos Therapeutics' current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics' Q4 2025 earnings at ($2.29) EPS, FY2025 earnings at ($8.19) EPS, Q1 2026 earnings at ($2.33) EPS, Q2 2026 earnings at ($2.45) EPS, Q3 2026 earnings at ($1.95) EPS, Q4 2026 earnings at ($2.04) EPS, FY2026 earnings at ($8.66) EPS, FY2027 earnings at ($6.81) EPS, FY2028 earnings at ($6.38) EPS and FY2029 earnings at ($6.26) EPS.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS traded up $0.36 during trading on Wednesday, hitting $10.20. The company had a trading volume of 112,747 shares, compared to its average volume of 63,314. The stock has a 50 day simple moving average of $8.19 and a 200 day simple moving average of $9.25. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The firm has a market capitalization of $62.73 million, a P/E ratio of -0.52 and a beta of 2.77.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $0.43 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its stake in shares of Aligos Therapeutics by 2,073.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock worth $26,000 after buying an additional 622 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after buying an additional 2,674 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Aligos Therapeutics by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock valued at $1,086,000 after buying an additional 3,197 shares in the last quarter. Northern Trust Corp purchased a new position in shares of Aligos Therapeutics during the 4th quarter valued at $205,000. Finally, XTX Topco Ltd purchased a new position in shares of Aligos Therapeutics during the 2nd quarter valued at $100,000. Institutional investors own 60.43% of the company's stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).